belopenem

Belopenem is a lung-targeted formulation of the carbapenem antibiotic meropenem, currently in preclinical development by Double Bond Pharmaceutical International. It utilizes the proprietary BeloGal drug delivery system, which is designed to concentrate the active pharmaceutical ingredient specifically in the lungs to treat bacterial pneumonia. By targeting the site of infection, Belopenem aims to achieve higher local concentrations of meropenem than standard systemic administration, potentially improving therapeutic efficacy while reducing systemic exposure and associated side effects. Meropenem, the active component, is a broad-spectrum antibiotic that acts by inhibiting bacterial cell wall synthesis through the binding and inhibition of penicillin-binding proteins (PBPs).

Other names

meropenem